

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 34-10921-03

Docket or Reference number
030-02809

Amendment No. 54

Bethesda Hospital
619 Oak Street
Cincinnati, OH 45206

In accordance with letter dated October 10, 1985, License Number 34-10921-03 is amended as follows:

Condition 12. is amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Eli Rubenstein, M.D.	All, except Group VI
William R. Dickens, M.D.	Diagnosis Group VI
Charles M. Barrett, M.D.	Diagnosis
Richard B. Mulvey, M.D.	Diagnosis Iodine-131 for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma
Nicholas R. Baumgartner, M.D.	Diagnosis
Jack A. Brucher, M.D.	Diagnosis
Charles H. Kuntz, M.D.	Diagnosis Iodine-131 for treatment of hyperthyroidism and cardiac dysfunction
Harry Horwitz, M.D.	Group VI
Pearl Compaan, M.D.	Group VI
Ann Weichart, M.D.	Group VI
Sudha B. Mahaligam, M.D.	Group VI
Richard H. Laib, M.D.	Diagnosis Iodine-131 for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 34-10921-03

Docket or Reference number
030-02809

Amendment No. 54

Kenneth Murdock, M.D.

Groups IV, V and VI

Thomas Michael Morand, M.D.

Group VI

Thomas E. Turek, M.D.

Diagnosis

Salomon Abas, M.D.

Groups I, II, III, IV and V

Susan Weinberg, M.D.

Groups I, II and III

Xenon-133

In vitro studies

Richard L. Levy, M.D.

Group VI

James Thomson, M.D.

Group VI

Julie Ann Farrell, M.D.

Groups I, II and III

Xenon-133

Iodine-131 for therapy

Phosphorus-32 in colloidal form
for intracavitary treatmentIn vitro studies

Michael Wolfson, M.D.

Groups I, II and III

Xenon-133

In vitro studies

Michael W. Zinda, M.D.

Group VI

For the U.S. Nuclear Regulatory Commission

Date

NOV 8 1985

Original Signed
By B. J. Holt

Materials Licensing Section, Region III

COPY